All In Biotech

NDA 020622 · Teva Pharms USA

Copaxone

Glatiramer Acetate · Subcutaneous

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Dec 20, 1996

Approved uses

3

Original approval plus efficacy supplements

Registered trials

83

27 Phase 3, 1 recruiting

FAERS reports

53,578

26,553 serious, 1,230 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ANAPHYLACTIC REACTIONS Cases of life-threatening and fatal anaphylaxis have been reported with COPAXONE. Anaphylaxis can occur at any time following initiation of therapy, from as early as after the first dose, up to years following initiation of therapy. Make patients aware of the symptoms of anaphylaxis, which may overlap with those of an immediate post-injection reaction; instruct them to seek immediate medical care should these symptoms occur. Prompt identification of anaphylaxis is important to avoid a delay in treatment [see Warnings and Precautions ( 5.1 )] . COPAXONE is contraindicated in patients with a history of hypersensitivity reactions to COPAXONE, including anaphylaxis. If an anaphylactic reaction occurs, treatment with COPAXONE must be immediately discontinued. Unless a clear alternative etiology is identified, COPAXONE must be permanently discontinued [see...

What it is approved for

From the label in effect Jun 23, 2026.

COPAXONE is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. COPAXONE is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ).

Mechanism: The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis, a condition induced in animals through immunization against central nervous system derived material containing myelin and often used as an experimental animal model of MS. Studies in animals and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 28, 2014 Supplement 89 · Efficacy ReviewLabelLetter
  • Feb 27, 2009 Supplement 57 · Efficacy LabelLetter
  • Dec 20, 1996 Original approval · Type 1 - New Molecular Entity Review
3 products under this application
  • COPAXONE · GLATIRAMER ACETATE 20MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
  • COPAXONE · GLATIRAMER ACETATE 40MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
  • COPAXONE · GLATIRAMER ACETATE 20MG/VIAL · FOR SOLUTION, SUBCUTANEOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Glatiramer" as an intervention, any sponsor and status, largest first.

All 83 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • multiple sclerosis relapse4,994
  • drug ineffective3,700
  • injection site pain3,648
  • injection site reaction3,121
  • fatigue3,040
  • multiple sclerosis2,954
  • dyspnoea2,672
  • fall2,398
  • gait disturbance1,983
  • pain1,801
  • injection site erythema1,797
  • nausea1,750

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004131
2005275
2006353
2007397
2008454
2009782
20101,251
20111,519
20121,790
20132,068
20144,339
20155,908
20166,614
20175,841
20185,222
20194,228
20202,729
20212,493
20222,375
20231,778
20241,347
20251,073
2026610

Recalls

3 FDA enforcement reports for this application.

  • Oct 24, 2013 · Class II · Terminated

    Presence of Particulate Matter: A foreign particle found in a pre-filled syringe was reported through a consumer complaint about a pre-filled syringe.

  • Dec 5, 2012 · Class II · Terminated

    Presence of Foreign Substance: Product is being recalled due to receiving an elevated number of patient complaints related to a visible presence of medical grade silicone oil essential to the functionality of the...

  • May 18, 2012 · Class II · Terminated

    Presence of Foreign Substance: Recall is being initiated due to the presence of a foreign particle identified from a customer complaint.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Copaxone (Glatiramer Acetate)

2024 spending

$257M

Beneficiaries

4,785

40,460 claims

Per beneficiary

$53,742

$428.54 per unit

View as table
YearSpending
2020$713,588,637
2021$556,474,219
2022$456,598,003
2023$369,370,974
2024$257,157,760

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 295 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.